NGS based RNA Sequencing Market

Report ID: SQMIG35J2751

BUY NOW GET SAMPLE REPORT

BUY NOW GET FREE SAMPLE

NGS based RNA Sequencing Market Size, Share, and Growth Analysis

Q: What is the key market trend for NGS based RNA Sequencing Market?

Clinical Adoption Acceleration: Healthcare providers are rapidly integrating NGS‑based RNA sequencing into routine diagnostics, driven by the need for precise molecular profiling and personalized therapy selection. The ability to detect gene expression changes, splice variants, and fusion transcripts enables clinicians to tailor treatments for oncology, rare diseases, and infectious conditions. As reimbursement frameworks evolve and evidence of clinical utility expands, hospitals and laboratories are prioritizing platform acquisition, staff training, and workflow optimization to meet growing patient demand for targeted interventions worldwide in practice.

NGS based RNA Sequencing Market By Sequencing Technology (Short-Read Sequencing, Long-Read Sequencing), By Workflow (Library Preparation, Sequencing, Data Analysis), By Application, By End User, By Region - Industry Forecast 2026-2033

Report ID: SQMIG35J2751 | Region: Global | Published Date: August, 2026
Pages: 157 |Tables: 117 |Figures: 77

Format -

NGS based RNA Sequencing Market Insights

Global Ngs Based Rna Sequencing Market size was valued at USD 3.9 Billion in 2024 and is poised to grow from USD 4.58 Billion in 2025 to USD 16.65 Billion by 2033, growing at a CAGR of 17.5% during the forecast period (2026-2033).

The NGS‑based RNA sequencing market comprises platforms and services that convert cellular RNA into reads, enabling transcriptome profiling for research, diagnostics, and drug development. Its importance stems from the ability to capture gene expression, splice variants, and non‑coding RNAs with depth, which fuels precision medicine initiatives. Historically, the market emerged from next‑generation sequencers in the mid‑2000s, but adoption accelerated after Illumina released its TruSeq RNA kits in 2012, reducing cost per sample below $100. Academic consortia such as GTEx and pharma projects like Novartis’ CAR‑T program illustrate how the technology has transitioned from niche to mainstream, creating an expanding ecosystem. Building on the growth outlined above, the driver accelerating the NGS‑based RNA sequencing market is the rising demand for transcriptomic data that guides therapeutic decisions. Oncology trials are adding RNA biomarkers to stratify patients, prompting providers to seek assays with turnaround, which pushes vendors toward automation and cloud analytics. Consequently, hospitals can adopt liquid‑biopsy RNA panels to monitor treatment response, as shown by a 500‑gene panel used for breast cancer at a cancer center. This clinical success spurs reimbursement changes and larger datasets for AI interpretation, creating a feedback loop that expands market size and attracts biotech and informatics entrants.

How is AI-driven automation influencing the NGS-based RNA sequencing market?

AI driven automation is reshaping the NGS based RNA sequencing market by streamlining every step from sample handling to data interpretation. Machine learning models now guide library preparation, predict optimal sequencing parameters and flag quality issues before runs begin. Automated liquid handling robots reduce manual errors while integrated analytics platforms turn raw reads into biologically meaningful results in minutes. This convergence shortens turnaround time, lowers costs and makes high throughput studies accessible to smaller labs. As researchers demand faster insights, AI tools are becoming essential components of modern sequencing pipelines, driving broader adoption across academic and clinical settingsIn June 2024, a leading sequencing platform launched an AI driven workflow automation suite that accelerates library preparation and cuts hands on time, enabling faster data delivery and supporting market growth through improved efficiency and scalability. The solution integrates real time quality monitoring and predictive maintenance, further reducing downtime and enhancing throughput for research and clinical laboratories

Market snapshot - (2026-2033)

Global Market Size

USD 3.9 Billion

Largest Segment

Instruments

Fastest Growth

Services

Growth Rate

17.5% CAGR

NGS based RNA Sequencing Market ($ Bn)

Country Share for North America Region (%)

To get more insights on this market click here to Request a Free Sample Report

NGS based RNA Sequencing Market Segments Analysis

Global ngs based rna sequencing market is segmented by sequencing technology, workflow, application, end user and region. Based on sequencing technology, the market is segmented into Short-Read Sequencing and Long-Read Sequencing. Based on workflow, the market is segmented into Library Preparation, Sequencing and Data Analysis. Based on application, the market is segmented into Transcriptome Profiling, Gene Expression Analysis, RNA Variant and Fusion Detection and Other Applications. Based on end user, the market is segmented into Academic and Research Institutes, Pharmaceutical and Biotechnology Companies and Hospitals and Diagnostic Laboratories. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

What role does short-read sequencing play in advancing transcriptome profiling in the ngs based rna sequencing market?

Short-Read Sequencing segment dominates because it offers high accuracy, mature chemistry, and cost efficiency that align with the bulk of RNA seq projects. Researchers favor it for large scale expression studies, and vendors have built extensive support ecosystems, reinforcing its market position. The reliability and throughput of short reads satisfy the demand for routine transcriptome profiling, cementing its leadership. Consequently, laboratories prioritize this technology when designing cost effective, high throughput RNA sequencing pipelines.

However, Long-Read Sequencing segment is witnessing the strongest growth momentum because its ability to capture full length transcripts resolves isoform complexity and structural variants. Emerging protocols and decreasing instrument costs are encouraging adoption in research and clinical settings, expanding the market’s scope beyond conventional expression analysis and creating new opportunities for RNA characterization.

how does transcriptome profiling influence the competitive dynamics of the ngs based rna sequencing market?

Transcriptome Profiling segment stands out because it provides comprehensive gene expression snapshots that are essential for basic research, drug target discovery, and biomarker identification. Its broad utility drives consistent demand across academic and commercial labs, prompting vendors to optimize kits and platforms for high throughput, reproducible results. This foundational role sustains its prominence within the market. Consequently, investment in assay development and data interpretation tools is heavily directed toward enhancing transcriptome depth and accuracy, reinforcing its market leadership.

On the other hand, RNA Variant and Fusion Detection segment emerges as the key high growth area because clinical oncology and rare disease diagnostics increasingly rely on precise identification of splice variants and gene fusions. Advances in bioinformatics pipelines and regulatory acceptance are accelerating its uptake, expanding market opportunities for specialized assays and driving broader adoption of NGS based RNA analysis.

NGS based RNA Sequencing Market By Product & Service

To get detailed segments analysis, Request a Free Sample Report

NGS based RNA Sequencing Market Regional Insights

Why does North America Dominate the Global NGS based RNA Sequencing Market?

North America leads through a convergence of world‑class research institutions, deep capital investment, and a culture of rapid technology adoption. The region hosts a dense network of pioneering biotech enterprises that collaborate closely with leading academic hospitals, accelerating translation of RNA sequencing breakthroughs into diagnostic and therapeutic tools. A supportive regulatory framework encourages innovative clinical trials, while a sophisticated supply chain ensures reliable access to reagents and instrumentation. Together these elements create an ecosystem where expertise, funding, and infrastructure reinforce each other, sustaining a leadership position in the global market.

United States NGS based RNA Sequencing Market

NGS based RNA Sequencing Market in United States benefits from a vibrant blend of academic excellence and entrepreneurial vigor. Leading research universities drive methodological advances, while a multitude of start‑ups and established firms translate discoveries into commercial platforms. Strong venture capital presence fuels continuous innovation, and close ties with federal research agencies promote collaborative projects that expand application breadth across health and life sciences sectors.

Canada NGS based RNA Sequencing Market

NGS based RNA Sequencing Market in Canada is propelled by a collaborative research community that emphasizes translational science. Government‑funded initiatives support infrastructure development and foster partnerships between universities and biotech firms. Emphasis on personalized medicine and genomic health drives demand, while a supportive policy environment facilitates integration of sequencing technologies into clinical practice and public health programs.

What is Driving the Rapid Expansion of NGS based RNA Sequencing Market in Europe?

Europe’s expansion is driven by a strong commitment to precision medicine, extensive public research funding, and a cohesive network of cross‑border collaborations. Leading academic consortia advance methodological standards, while a growing number of biotech hubs translate these advances into market‑ready solutions. Harmonized regulatory pathways encourage clinical adoption, and an emphasis on sustainable innovation nurtures partnerships between industry and healthcare systems. This collective momentum positions Europe as a dynamic arena for RNA sequencing growth and application diversification.

Germany NGS based RNA Sequencing Market

NGS based RNA Sequencing Market in Germany thrives on a well‑established research infrastructure and a tradition of engineering excellence. Major universities and research institutes generate cutting‑edge protocols, while a dense cluster of technology providers supplies high‑quality instruments and consumables. Strong public and private funding mechanisms support both basic science and translational projects, encouraging a seamless pipeline from discovery to clinical implementation.

United Kingdom NGS based RNA Sequencing Market

NGS based RNA Sequencing Market in United Kingdom accelerates through a vibrant biotech ecosystem and proactive governmental support for genomic initiatives. Renowned research hospitals and universities drive clinical validation, while a flourishing start‑up scene injects novel analytical tools into the market. Collaborative frameworks across Europe and close links with regulatory bodies streamline adoption of RNA sequencing in both research and diagnostic settings.

France NGS based RNA Sequencing Market

NGS based RNA Sequencing Market in France benefits from a strategic focus on health innovation and strong public research institutions. Collaborative programs link academic laboratories with emerging biotech firms, fostering the development of bespoke sequencing applications. National health agencies promote integration of RNA sequencing into personalized care pathways, creating a fertile environment for continued market emergence.

How is Asia Pacific Strengthening its Position in NGS based RNA Sequencing Market?

Asia Pacific advances its position through a blend of rapid technological uptake, expanding research capacity, and increasing integration of sequencing into clinical and agricultural settings. Governments prioritize genomics as a pillar of economic development, encouraging investment in state‑of‑the‑art facilities and talent development. Partnerships between multinational corporations and local innovators accelerate knowledge transfer, while a growing emphasis on disease‑specific studies drives demand for RNA sequencing solutions across diverse health landscapes. This coordinated approach elevates the region’s influence in the global market.

Japan NGS based RNA Sequencing Market

NGS based RNA Sequencing Market in Japan is reinforced by a sophisticated scientific community and a strong emphasis on precision health. Leading universities and research centers pioneer methodological refinements, while collaborative ventures with global technology providers ensure access to cutting‑edge platforms. Governmental programs support translational research, fostering the movement of sequencing insights from bench to bedside and enhancing clinical relevance.

South Korea NGS based RNA Sequencing Market

NGS based RNA Sequencing Market in South Korea is propelled by a dynamic biotech sector and a culture of rapid innovation adoption. Academic hospitals and research institutes drive application‑focused studies, while a network of agile start‑ups develops customized bioinformatics solutions. Strategic public investment accelerates infrastructure expansion, positioning the country as a hub for both clinical and agricultural RNA sequencing advancements.

NGS based RNA Sequencing Market By Geography

Largest
Fastest

To know more about the market opportunities by region and country, click here to
Buy The Complete Report

NGS based RNA Sequencing Market Dynamics

Drivers

Expanding Clinical Applications are Fueling Demand

The increasing use of RNA sequencing in oncology, infectious disease monitoring, and personalized medicine creates a persistent demand for high‑throughput platforms, encouraging laboratories to adopt next‑generation sequencing solutions that can deliver comprehensive transcriptomic profiles. This clinical relevance motivates investment in sophisticated instruments and software, fostering a cycle where expanding diagnostic capabilities further stimulate market uptake, as healthcare providers seek detailed molecular insights to guide treatment decisions and improve patient outcomes, thereby driving sustained market expansion. Regulatory guidance reduces barriers, encouraging broader clinical adoption and further integration.

Advancements In Throughput and Accuracy

Recent innovations in sequencing chemistry and hardware have significantly increased read length, accuracy, and multiplexing capacity, enabling researchers to capture complex transcriptomes with fewer errors. These technological improvements lower the time required for data generation and simplify experimental design, making RNA sequencing more attractive for large‑scale studies. As laboratories experience enhanced reliability and cost‑effectiveness, they are more likely to expand their service offerings, which in turn fuels broader market penetration and reinforces the perception of NGS‑based RNA sequencing as a standard research tool.

Restraints

High Capital Investment is Limiting Adoption

The substantial upfront cost of acquiring NGS platforms, coupled with ongoing expenses for consumables and maintenance, poses a financial barrier for many academic and clinical laboratories. Budget constraints often force institutions to prioritize established technologies or limit the scale of RNA sequencing projects, slowing broader adoption. This financial pressure can delay investment decisions, reduce the frequency of experiments, and curtail the overall market growth, as potential customers seek more affordable alternatives or postpone implementation until funding improves within the next fiscal periods.

Data Interpretation Complexity is Slowing Integration

Interpreting the vast and complex data generated by RNA sequencing requires specialized bioinformatics expertise and robust computational infrastructure, which many organizations lack. The steep learning curve for data analysis and the need for continuous software updates can deter laboratories from fully integrating NGS‑based workflows. Consequently, project timelines may extend, and the perceived risk of erroneous conclusions can inhibit investment, thereby slowing market expansion as potential users await more user‑friendly solutions and comprehensive support services and streamlined data pipelines that reduce complexity for routine clinical use.

Request Free Customization of this report to help us to meet your business objectives.

NGS based RNA Sequencing Market Competitive Landscape

SeqOne Genomics: Established in 2022, their main objective is to accelerate AI‑driven NGS platforms for personalized medicine. Recent development: secured €20 million in an oversubscribed growth round in May 2025 to expand AI analytics pipeline and launch a cloud‑based RNA‑seq service across Europe and North America. The funding will also support hiring of bioinformatics talent, integration of machine‑learning models for splice‑variant detection, and partnership with major hospital networks to pilot clinical studies. These initiatives aim to position SeqOne as a leader in clinical RNA‑seq analytics.

Alethiomics: Established in 2020, their main objective is to provide scalable single‑cell RNA‑seq solutions for drug discovery. Recent development: closed a $15 million Series A round in June 2025 to launch an automated library‑prep instrument and sign distribution agreements with European OEMs. The platform leverages microfluidic droplet technology to capture transcriptional profiles from thousands of cells simultaneously, reducing per‑sample cost and enabling high‑throughput phenotypic screens. Alethiomics also announced a collaboration with a major biotech hub in Boston to integrate its data pipeline into existing CRISPR screening workflows, aiming to accelerate target validation.

Top Player’s Company Profile

Illumina, Inc.

Thermo Fisher Scientific Inc.

Pacific Biosciences of California, Inc.

Oxford Nanopore Technologies Ltd.

BGI Group

QIAGEN N.V.

Agilent Technologies, Inc.

F. Hoffmann-La Roche Ltd.

Merck KGaA

Revvity, Inc.

Takara Bio Inc.

Zymo Research Corp.

Eurofins Scientific SE

Azenta, Inc.

Psomagen, Inc.

Novogene Corporation

Macrogen, Inc.

Tecan Group AG

Hamilton Company

Bio-Rad Laboratories, Inc.

Recent Developments

Illumina announced a new multi‑omics library preparation system in March 2025, enabling simultaneous DNA, RNA and protein profiling on its NovaSeq platforms. The solution integrates streamlined chemistry with advanced automation, reducing hands‑on time and improving data consistency across omics layers, thereby accelerating discovery pipelines in translational research, drug development and precision medicine initiatives.

Thermo Fisher Scientific introduced an upgraded Ion Torrent RNA‑seq kit in June 2025, featuring streamlined library construction, enhanced read accuracy and expanded multiplexing capacity. The kit supports rapid transcriptome profiling from low‑input samples, integrates with the company's cloud‑based analysis platform, and is positioned to meet growing demand for clinical diagnostics, oncology research and infectious disease monitoring.

Oxford Nanopore Technologies launched a high‑throughput direct RNA sequencing flow cell in September 2025, delivering ultra‑long reads and real‑time data streaming on the PromethION platform. The flow cell incorporates improved nanopore chemistry and adaptive sampling, allowing comprehensive isoform detection and quantitative expression analysis from native RNA, facilitating advanced studies in neurobiology, immunology and plant genomics.

NGS based RNA Sequencing Key Market Trends

Clinical Adoption Acceleration: Healthcare providers are rapidly integrating NGS‑based RNA sequencing into routine diagnostics, driven by the need for precise molecular profiling and personalized therapy selection. The ability to detect gene expression changes, splice variants, and fusion transcripts enables clinicians to tailor treatments for oncology, rare diseases, and infectious conditions. As reimbursement frameworks evolve and evidence of clinical utility expands, hospitals and laboratories are prioritizing platform acquisition, staff training, and workflow optimization to meet growing patient demand for targeted interventions worldwide in practice.

Cloud‑Enabled Data Collaboration: Researchers are increasingly leveraging cloud‑based platforms to store, process, and share massive RNA‑seq datasets, eliminating the constraints of on‑premise infrastructure. These services provide scalable compute power, integrated bioinformatics pipelines, and secure collaborative workspaces, facilitating multi‑institutional studies and rapid hypothesis testing. By abstracting hardware management, teams can focus on experimental design and interpretation, accelerating discovery cycles. The shift toward cloud ecosystems also supports reproducibility standards and fosters open science initiatives across academic, biotech, and pharmaceutical sectors, driving innovation and competitive advantage.

NGS based RNA Sequencing Market SkyQuest Analysis

SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research. As per SkyQuest analysis the global NGS‑based RNA sequencing market is projected to climb from $4.58 billion in 2025 to $16.65 billion by 2033, driven first by expanding clinical applications such as oncology and infectious‑disease diagnostics that demand comprehensive transcriptomic data. A second driver is rapid improvement in throughput and accuracy enabled by newer chemistry and AI‑enhanced automation, which lowers cost and speeds results. The market is chiefly led by North America where strong research institutions, venture capital and supportive regulation fuel adoption. Short‑read sequencing remains the dominant segment because of its high accuracy and cost‑effectiveness, while the high capital investment required for instruments and consumables acts as a key restraint limiting broader uptake.

Report Metric	Details
Market size value in 2024	USD 3.9 Billion
Market size value in 2033	USD 16.65 Billion
Growth Rate	17.5%
Base year	2024
Forecast period	(2026-2033)
Forecast Unit (Value)	USD Billion
Segments covered	Sequencing Technology Short-Read Sequencing Long-Read Sequencing Workflow Library Preparation Sequencing Data Analysis Application Transcriptome Profiling Gene Expression Analysis RNA Variant and Fusion Detection Other Applications End User Academic and Research Institutes Pharmaceutical and Biotechnology Companies Hospitals and Diagnostic Laboratories
Regions covered	North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA)
Companies covered	Illumina, Inc. Thermo Fisher Scientific Inc. Pacific Biosciences of California, Inc. Oxford Nanopore Technologies Ltd. BGI Group QIAGEN N.V. Agilent Technologies, Inc. F. Hoffmann-La Roche Ltd. Merck KGaA Revvity, Inc. Takara Bio Inc. Zymo Research Corp. Eurofins Scientific SE Azenta, Inc. Psomagen, Inc. Novogene Corporation Macrogen, Inc. Tecan Group AG Hamilton Company Bio-Rad Laboratories, Inc.
Customization scope	Free report customization with purchase. Customization includes:- Segments by type, application, etc Company profile Market dynamics & outlook Region

To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.

Table Of Content

Executive Summary

Market overview

Exhibit: Executive Summary – Chart on Market Overview
Exhibit: Executive Summary – Data Table on Market Overview
Exhibit: Executive Summary – Chart on NGS based RNA Sequencing Market Characteristics
Exhibit: Executive Summary – Chart on Market by Geography
Exhibit: Executive Summary – Chart on Market Segmentation
Exhibit: Executive Summary – Chart on Incremental Growth
Exhibit: Executive Summary – Data Table on Incremental Growth
Exhibit: Executive Summary – Chart on Vendor Market Positioning

Parent Market Analysis

Market overview

Market size

Market Dynamics
- Exhibit: Impact analysis of DROC, 2021
  - Drivers
  - Opportunities
  - Restraints
  - Challenges
SWOT Analysis

KEY MARKET INSIGHTS

Technology Analysis
- (Exhibit: Data Table: Name of technology and details)
Pricing Analysis
- (Exhibit: Data Table: Name of technology and pricing details)
Supply Chain Analysis
- (Exhibit: Detailed Supply Chain Presentation)
Value Chain Analysis
- (Exhibit: Detailed Value Chain Presentation)
Ecosystem Of the Market
- Exhibit: Parent Market Ecosystem Market Analysis
- Exhibit: Market Characteristics of Parent Market
IP Analysis
- (Exhibit: Data Table: Name of product/technology, patents filed, inventor/company name, acquiring firm)
Trade Analysis
- (Exhibit: Data Table: Import and Export data details)
Startup Analysis
- (Exhibit: Data Table: Emerging startups details)
Raw Material Analysis
- (Exhibit: Data Table: Mapping of key raw materials)
Innovation Matrix
- (Exhibit: Positioning Matrix: Mapping of new and existing technologies)
Pipeline product Analysis
- (Exhibit: Data Table: Name of companies and pipeline products, regional mapping)
Macroeconomic Indicators

COVID IMPACT

Introduction
Impact On Economy—scenario Assessment
- Exhibit: Data on GDP - Year-over-year growth 2016-2022 (%)
Revised Market Size
- Exhibit: Data Table on NGS based RNA Sequencing Market size and forecast 2021-2027 ($ million)
Impact Of COVID On Key Segments
- Exhibit: Data Table on Segment Market size and forecast 2021-2027 ($ million)
COVID Strategies By Company
- Exhibit: Analysis on key strategies adopted by companies

MARKET DYNAMICS & OUTLOOK

Market Dynamics
- Exhibit: Impact analysis of DROC, 2021
  - Drivers
  - Opportunities
  - Restraints
  - Challenges
Regulatory Landscape
- Exhibit: Data Table on regulation from different region
SWOT Analysis
Porters Analysis
- Competitive rivalry
  - Exhibit: Competitive rivalry Impact of key factors, 2021
- Threat of substitute products
  - Exhibit: Threat of Substitute Products Impact of key factors, 2021
- Bargaining power of buyers
  - Exhibit: buyers bargaining power Impact of key factors, 2021
- Threat of new entrants
  - Exhibit: Threat of new entrants Impact of key factors, 2021
- Bargaining power of suppliers
  - Exhibit: Threat of suppliers bargaining power Impact of key factors, 2021
Skyquest special insights on future disruptions
- Political Impact
- Economic impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact

Market Size by Region

Chart on Market share by geography 2021-2027 (%)
Data Table on Market share by geography 2021-2027(%)
North America
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- USA
  - Exhibit: Chart on Market share 2021-2027 (%)
  - Exhibit: Market size and forecast 2021-2027 ($ million)
- Canada
  - Exhibit: Chart on Market share 2021-2027 (%)
  - Exhibit: Market size and forecast 2021-2027 ($ million)
Europe
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- Germany
  - Exhibit: Chart on Market share 2021-2027 (%)
  - Exhibit: Market size and forecast 2021-2027 ($ million)
- Spain
  - Exhibit: Chart on Market share 2021-2027 (%)
  - Exhibit: Market size and forecast 2021-2027 ($ million)
- France
  - Exhibit: Chart on Market share 2021-2027 (%)
  - Exhibit: Market size and forecast 2021-2027 ($ million)
- UK
  - Exhibit: Chart on Market share 2021-2027 (%)
  - Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of Europe
  - Exhibit: Chart on Market share 2021-2027 (%)
  - Exhibit: Market size and forecast 2021-2027 ($ million)
Asia Pacific
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- China
  - Exhibit: Chart on Market share 2021-2027 (%)
  - Exhibit: Market size and forecast 2021-2027 ($ million)
- India
  - Exhibit: Chart on Market share 2021-2027 (%)
  - Exhibit: Market size and forecast 2021-2027 ($ million)
- Japan
  - Exhibit: Chart on Market share 2021-2027 (%)
  - Exhibit: Market size and forecast 2021-2027 ($ million)
- South Korea
  - Exhibit: Chart on Market share 2021-2027 (%)
  - Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of Asia Pacific
  - Exhibit: Chart on Market share 2021-2027 (%)
  - Exhibit: Market size and forecast 2021-2027 ($ million)
Latin America
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- Brazil
  - Exhibit: Chart on Market share 2021-2027 (%)
  - Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of South America
  - Exhibit: Chart on Market share 2021-2027 (%)
  - Exhibit: Market size and forecast 2021-2027 ($ million)
Middle East & Africa (MEA)
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- GCC Countries
  - Exhibit: Chart on Market share 2021-2027 (%)
  - Exhibit: Market size and forecast 2021-2027 ($ million)
- South Africa
  - Exhibit: Chart on Market share 2021-2027 (%)
  - Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of MEA
  - Exhibit: Chart on Market share 2021-2027 (%)
  - Exhibit: Market size and forecast 2021-2027 ($ million)

KEY COMPANY PROFILES

Competitive Landscape
- Total number of companies covered
  - Exhibit: companies covered in the report, 2021
- Top companies market positioning
  - Exhibit: company positioning matrix, 2021
- Top companies market Share
  - Exhibit: Pie chart analysis on company market share, 2021(%)

Methodology

For the NGS based RNA Sequencing Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:

1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.

2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the NGS based RNA Sequencing Market.

3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.

4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.

Analyst Support

Customization Options

With the given market data, our dedicated team of analysts can offer you the following customization options are available for the NGS based RNA Sequencing Market:

Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.

Regional Analysis: Further analysis of the NGS based RNA Sequencing Market for additional countries.

Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.

Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.

Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.

Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.

Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.

Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.

License Type Top market research company in USA

File Type

$5,300

BUY NOW

ADD TO CART

REQUEST FOR SAMPLE

GET FREE SAMPLE

Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

The global NGS‑based RNA‑sequencing market is shaped by intense competition as leading providers race to embed artificial‑intelligence, expand geographic reach, and secure strategic assets. Illumina has accelerated its portfolio through recent alliances with cloud‑computing firms and the acquisition of a boutique bioinformatics company, while SeqOne Genomics leverages AI‑driven pipelines to differentiate its clinical RNA‑seq services. 'Illumina, Inc.', 'Thermo Fisher Scientific Inc.', 'Pacific Biosciences of California, Inc.', 'Oxford Nanopore Technologies Ltd.', 'BGI Group', 'QIAGEN N.V.', 'Agilent Technologies, Inc.', 'F. Hoffmann-La Roche Ltd.', 'Merck KGaA', 'Revvity, Inc.', 'Takara Bio Inc.', 'Zymo Research Corp.', 'Eurofins Scientific SE', 'Azenta, Inc.', 'Psomagen, Inc.', 'Novogene Corporation', 'Macrogen, Inc.', 'Tecan Group AG', 'Hamilton Company', 'Bio-Rad Laboratories, Inc.'

The increasing use of RNA sequencing in oncology, infectious disease monitoring, and personalized medicine creates a persistent demand for high‑throughput platforms, encouraging laboratories to adopt next‑generation sequencing solutions that can deliver comprehensive transcriptomic profiles. This clinical relevance motivates investment in sophisticated instruments and software, fostering a cycle where expanding diagnostic capabilities further stimulate market uptake, as healthcare providers seek detailed molecular insights to guide treatment decisions and improve patient outcomes, thereby driving sustained market expansion. Regulatory guidance reduces barriers, encouraging broader clinical adoption and further integration.

Clinical Adoption Acceleration: Healthcare providers are rapidly integrating NGS‑based RNA sequencing into routine diagnostics, driven by the need for precise molecular profiling and personalized therapy selection. The ability to detect gene expression changes, splice variants, and fusion transcripts enables clinicians to tailor treatments for oncology, rare diseases, and infectious conditions. As reimbursement frameworks evolve and evidence of clinical utility expands, hospitals and laboratories are prioritizing platform acquisition, staff training, and workflow optimization to meet growing patient demand for targeted interventions worldwide in practice.

Why does North America Dominate the Global NGS based RNA Sequencing Market? |@12

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

Request Customization

Feedback From Our Clients

"We have purchased recently a report from SkyQuest Technology, and we are happy to inform you that this report was so useful and practical for our team. Skyquest Team was very active and our queries were followed up completely.It was amazing. "

- Mr. Luca Giovannini, Marketing Innovation Senior Manager, Trelleborg.